Puyallup hospital's new robotic technology revolutionizes lung cancer diagnosis
New robotic technology has arrived at Puyallup's MultiCare Good Samaritan Hospital – and it creates a world of difference for lung cancer patients in Pierce County.
The DaVinci ION robotic surgery system is used during lung biopsies, where doctors find lung growths and gather the information they need for treatment.
'This is a worldwide phenomenon,' said Abhishek Biswas, a pulmonologist at MultiCare. 'It was much harder to get a stage 1 diagnosis before the advent of this ION.'
Biswas told The News Tribune the technology came out around 2019 or 2020, and MultiCare first acquired it in 2022. Good Samaritan Hospital acquired the new system in April.
'We wanted to expand [to Good Samaritan] — not as a big business venture, but to make sure patients have care close to home,' Biswas said. 'Get treated and, subsequently, get care.'
The News Tribune asked MultiCare how much it cost them to acquire the technology, but they declined to say.
The procedure happens after a doctor has run a CT scan on someone and detected nodules in their lungs.
'We need to know if the nodule is malignant or benign — if it is cancer, what type of cancer? What is the stage?' Biswas said. 'This procedure gives us answers to all three of these questions at the very outset.'
It is not a surgery, Biswas said, it is a minimally-invasive procedure. The doctor gives the patient general anesthesia and conducts X-rays — then puts a needle and probe down the patient's mouth. The tools go down the throat, through the trachea and down to the lungs.
On another screen, doctors use the patient's previous CT scan to map a path to the nodule.
'It generates a map to reach into the nodule, into the lung, and once we actually have that map ready, we go down the mouth with a tiny catheter on my way into the nodule,' Biswas said.
This helps with accuracy, Biswas said, as the nodule is constantly changing positions as the patient breathes.
After the procedure, patients can get a diagnosis as early as 45 minutes after doctors wrap up, Biswas said.
Biswas told The News Tribune the procedure is covered under Medicaid, Medicare and private insurance. He has not seen any denials.
Before the ION system came out, doctors couldn't do anything if the lung nodules were less than a centimeter. Instead, they were forced to wait until the nodules grew to a size where they could perform the procedure and get information they needed about the growth.
'Historically, the strategy has been we used to have a scan for this photo and [then] watch them grow and do another scan – and only when it reached a substantial size would someone be able to get tissue from that,' Biswas said. '[Patients] have the knowledge there to make a decision on what they want to do next … no normal human being likes to be in a situation with so much uncertainty.'
Biswas said that while only 4% of nodules are malignant, it is important to catch potential cancer as early as possible. The five-year survival rate for lung cancer patients was more than 80% when detected during stage 1 — significantly more than the 60% five-year survival rate at stage 2.
'The whole idea is, we are trying to identify lung cancer in the early stages so we don't have loss of lung functions or quality of life,' Biswas said.
This procedure used to be two different procedures, Biswas said, until the ION system allowed doctors to combine them into one. It also used to be a lot more invasive, with doctors making a puncture in the chest and reaching into the tissue until they found the nodule.
'[It's] 1/20th of the risk that we did before — so, so much better for the patients,' Biswas said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nevada health bill advances to Gov. Lombardo's desk
LAS VEGAS (KLAS) – Health bill SB 217 advanced in the Nevada legislature last week and is now on Governor Lombardo's desk awaiting his signature. The bill includes coverage for treatments like IVF, as well as fertility preservation for those who have been diagnosed with extreme illness. 'I had arthritis for most of my life. That drug that I was on, while helpful to my arthritis, was severely damaging to my egg reserves,' shared Stephanie Capellas-Glascock, who has been struggling with her infertility journey for years. 'I knew that it wasn't going to be something that I could accomplish on my own, so therefore I needed to look into fertility treatments for myself,' she explained. If signed, Nevada could become the first state in the nation to offer fertility coverage for Medicaid. However, the bill does face pushback for its cost and certain language in it. 'One of my concerns, just looking at it, so I may reserve my right to change my vote, is just the financial impact on our public employee benefit program that can go down to increasing premiums,' said Democratic Assembly Member Shea Backus, who did vote in favor. Meanwhile, the Nevada GOP party called on the governor to veto the bill. Their website cited their opposition because it 'declares embryos prior to implantation as non-human.' 'I don't think fertility treatments are a political issue. I think it's a health and medical issue,' Capellas-Glascock responded when asked about the opposition. 'We know that the GOP has some thoughts and feelings on that too, but I think the tremendous thing about IVF is that it is a miracle in medicine and science that really affords individuals the option to have a family, so when they're ready to start a family, they have that option.' When asked about the fiscal implications, she responded, 'There's always a cost associated. I think it's knowing that the pros supremely outweigh the cons.' The state estimated the cost would be about $38 million over the next two years. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Medscape
3 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
Yahoo
4 hours ago
- Yahoo
The impact of Medicaid, SNAP cuts in Trump's ‘big, beautiful bill'
ST. LOUIS – Last week, the nonpartisan Congressional Budget Office (CBO) issued its analysis of President Donald Trump's so-called 'big, beautiful bill.' The CBO predicted the legislation would increase the federal deficit by $2.4 trillion over the next decade and leave nearly 11 million people without health insurance. 'They're asking the poorest Americans to tighten their belts, so that the richest Americans can loosen their belts, and that's what makes it so extra unfair,' Bobby Kogan, senior director of federal budget policy at the Center for American Progress, said. Kogan says the president's tax bill could feature the largest Medicaid and Supplemental Nutrition Assistance Program (SNAP) cuts in history. 'By putting up so much red tape, tons of people who're doing everything right fall through the cracks,' Kogan said. 'These are incredibly meager benefits and all of the sudden, lots of people are going to lose them.' Police crackdown on reckless, disabling dozens of cars Kogan says the bill freezes Medicaid provider taxes, which many states use to help pay for large portions of their Medicaid programs. 'Already, a lot of hospitals are struggling, and this would definitely make the situation much worse,' he said. Senator Josh Hawley warned this could force rural hospitals to close. 'You've got some senators who now want to change this bill to cut Medicaid benefits. That's ridiculous. That's insane. 1.3 million people in Missouri are on Medicaid, including hundreds of thousands of kids. These are working people who cannot afford health insurance otherwise,' Hawley said in a June 5 interview. Last week, Hawley posted on his X social media account, 'Just had a great talk with President Trump about the big, beautiful bill. He said again, no Medicaid benefit cuts.' 'Failure is not an option. And we intend to deliver, along with the president, for the American people,' Senate Majority Leader John Thune, R-S.D., said. With Senate Republicans planning to get the bill to the president's desk by July 4, Kogan fears the fallout. 'There's a lot at stake here and a lot of people's livelihoods could be upended, so I hope the senators could see differently,' Kogan said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
